<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Glucarpidase</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08898</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Glucarpidase is the recombinant form of the enzyme carboxypeptidase that is produced in Esherichia coli. In patients, glucarpidase inactivates methotrexate, and other antifolates, by hydrolyzing glutamate on the carboxyl terminal of these compounds. Therefore since methotrexate is elminated enzymatically and not by the kidneys, glucarpidase is indicated in patients on methotrexate treatment who have kidney dysfunction, and are experiencing an abnormally high plasma concentration of methotrexate (&gt;1 micromole per liter). Glucarpidase is marketed under the brand name Voraxaze&#174;.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>1950</sub>H<sub>3157</sub>N<sub>543</sub>O<sub>599</sub>S<sub>7</sub></td></tr><tr><th>Protein average weight</th><td>44016.6653 g/mol</td></tr><tr><th>Sequences</th><td></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Carboxypeptidase G2 </td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Voraxaze</td><td>BTG International Inc</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/enzymes">Enzymes</a></li></ul></td></tr><tr><th>CAS number</th><td>9074-87-7</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in patients on methotrexate treatment who have kidney dysfunction, and are experiencing an abnormally high plasma concentration of methotrexate (&gt; 1 micromole per liter).</td></tr><tr><th>Pharmacodynamics</th><td>Glucarpidase acts as an antidote to toxic methotrexate levels by elminating methotrexate by a non-kidney route.</td></tr><tr><th>Mechanism of action</th><td>Glucarpidase inactivates methotrexate, and other antifolates, by hydrolyzing glutamate on the carboxyl terminal of these compounds. For methotrexate specifically, it is hydrolyzed to the inactive metabolites glutamate and 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA).</td></tr><tr><th>Absorption</th><td>In healthy patients not taking methotrexate, the average maximum concentration for glucarpidase was 3.3 &#956;g/mL.</td></tr><tr><th>Volume of distribution</th><td><p>Glucarpidase is likely limited to the plasma volume since its volume of distribution is 3.6 L.</p></td></tr><tr><th>Protein binding</th><td>Plasma protein binding was not quantified.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolism was not determined.</p></td></tr><tr><th>Route of elimination</th><td>Route of elmination was not determined.</td></tr><tr><th>Half life</th><td>In healthy patients not taking methotrexate, glucarpidase has an elimination half-life of 5.6 hours. In patients with severe renal impairment (creatinine clearance </td></tr><tr><th>Clearance</th><td><p>In healthy patients not taking methotrexate, glucarpidase has a clearance of 7.5 mL/min.</p></td></tr><tr><th>Toxicity</th><td>Most common adverse reactions include hypotension, flushing, nausea, vomiting, headache, and paresthesia.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, lyophilized, for solution</td><td>Intravenous</td><td>1000 UNITS PER VIAL </td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Green JM: Glucarpidase to combat toxic levels of methotrexate in patients. Ther Clin Risk Manag. 2012;8:403-13. doi: 10.2147/<span class="caps">TCRM</span>.S30135. Epub 2012 Nov 22. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23209370">Pubmed</a></li>
	<li>Tuffaha HW, Al Omar S: Glucarpidase for the treatment of life-threatening methotrexate overdose. Drugs Today (Barc). 2012 Nov;48(11):705-11. doi: 10.1358/dot.2012.48.11.1871575. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23170306">Pubmed</a></li>
	<li><span class="caps">FDA</span> label.</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>UniProt</td><td><a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P06621" target="_blank">P06621 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/voraxaze-drug.htm" target="_blank">http://www.rxlist.com/voraxaze-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/mtm/glucarpidase.html" target="_blank">http://www.drugs.com/mtm/glucarpidase.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Glucarpidase" target="_blank">Glucarpidase <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>V03AF09<ul class="atc-drug-tree"><li><a href="/atc/V#V">V &#8212; VARIOUS</a></li><li><a href="/atc/V03#V03">V03 &#8212; ALL OTHER THERAPEUTIC PRODUCTS</a></li><li><a href="/atc/V03A#V03A">V03A &#8212; ALL OTHER THERAPEUTIC PRODUCTS</a></li><li><a href="/atc/V03AF#V03AF">V03AF &#8212; Detoxifying agents for antineoplastic treatment</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB08898.pdf?1370406330">show</a>(367 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB08898.pdf?1370407665">show</a>(83.7 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00650">Leucovorin</a></td><td>Do not administer leucovorin within 2 hours of glucarpidase due to the fact that leucovorin is degraded by glucarpidase.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>No food effects were found.</li></ul></td></tr></tbody></table>